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ABSTRACT  
Obesity is a prevalent global public health issue characterised by excess body 
fat.  Adipose tissue is now recognised as an important endocrine organ releasing an 
abundance of bioactive adipokines including, but not limited to, leptin, adiponectin 
and resistin. Obesity is a common co-morbidity amongst pulmonary arterial 
hypertension (PAH) patients, with 30-40% reported as obese, independent of other 
co-morbidities associated with PAH (e.g. obstructive sleep apnoea).  An “obesity 
paradox” has been observed, where obesity has been associated with subclinical RV 
dysfunction but paradoxically may confer a protective effect on RV function once 
pulmonary hypertension develops.  
Obesity and PAH share multiple pathophysiological mechanisms including 
inflammation, oxidative stress, elevated leptin (pro-inflammatory) and reduced 
adiponectin (anti-inflammatory). The female-prevalence of PAH has instigated the 
hypothesis that estrogens may play a causative role in its development. Adipose 
tissue, a major site for storage and metabolism of sex steroids, is the primary source 
of estrogens and circulating estrogens levels which are elevated in post-menopausal 
women and men with PAH. This review discusses the functions of adipose tissue in 
both health and obesity and the links between obesity and PAH.  Shared 
pathophysiological mechanisms and the contribution of specific fat depots, metabolic 
and sex-dependent differences are discussed. 
KEYWORDS:  Aromatase, metabolic syndrome, sex differences 
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INTRODUCTION 
Obesity is a growing public health problem worldwide and its rising prevalence 
will likely contribute to an increased burden from several diseases, notably, 
cardiovascular disease, diabetes, and cancer. Comorbidities are common amongst 
pulmonary arterial hypertension (PAH) patients and 30-40% of patients with PAH are 
reported as obese.1-3  Obesity has been linked to sleep disordered breathing and 
hypoventilation which may contribute to hypertensive changes in the pulmonary 
circulation. Indeed, histological changes indicative of pulmonary arterial and venous 
hypertension are present in a number of obese individuals without PAH.4  
Furthermore, adipose tissue is now recognized as an important endocrine organ and 
the excess accumulation of body fat that occurs in obesity can result in chronic low-
grade inflammation, insulin resistance and adipose tissue dysfunction that may 
contribute to the pathogenesis of PAH.   
Adipose tissue dysfunction in obesity results in a marked change in the profile 
of bioactive mediators produced.  The altered secretion of such mediators from 
adipose tissue can contribute both directly and indirectly to the development of 
obesity-related diseases.5  Of interest, adipose tissue synthesises estrogen and 
adipose tissue expansion in obesity is known to contribute to development of 
estrogen-sensitive breast cancer.6  Adipose tissue contains high levels of the 
estrogen metabolising enzyme cytochrome P450 1B1 (CYP1B1) and in obese mice 
thoracic adipose tissue produces 16α-hydroxyestrone (16OHE1),7 a known mitogen 
in the pulmonary circulation.8  It is also thought that 16OHE1 can increase the 
penetrance of mutations in bone morphogenetic protein receptor 2 (BMPR2) both 
experimentally and clinically.9  
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 Mechanisms associating obesity to PAH are not well understood, 
however both conditions share several underlying pathological mechanisms.  The 
metabolic changes that arise in obese individuals may contribute to the development 
of a pathophysiological environment that facilitates pulmonary vascular remodelling 
contributing to the development and/or exacerbation of PAH.  This review will focus 
on adipose tissue dysfunction in obesity, adipose-derived estrogens, sex-dependent 
differences and the contribution of specific fat depots and their role in PAH 
development and disease pathobiology.   
OBESITY AND ADIPOSE TISSUE DYSFUNCTION  
 Obesity is characterised by an excessive amount of body fat and an increased 
BMI of 30kg/m2 and above.   The composition of adipose tissue dramatically 
changes in obesity, involving alterations in adipose size and number, immune cell 
content and extracellular matrix resulting in a predisposition to metabolic dysfunction.   
 Chronic availability of excess nutrients leads to the expansion of fat depots, 
weight gain and obesity.  Adipose tissue can expand by two main mechanisms: 
hypertrophy and hyperplasia.  Hypertrophy involves increasing the size of individual 
adipocytes, whilst hyperplasia recruits new adipocytes from a reservoir of resident 
progenitor cells.  The capacity of adipose tissue to expand is critical for 
accommodating changes in energy availability, but this capacity is not an unlimited 
process and varies between individuals.10  In obese humans, hypertrophy of 
adipocytes correlates with dyslipidemia, impaired glucose homeostasis and 
inflammation.  Conversely, adipocyte size was found to be smaller in obese 
individuals without metabolic disease compared to those with metabolic 
complications.11  These observations suggest that large adipocytes are pathogenic 
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and/or the inability of adipocytes to further expand limits the capacity for excess lipid 
storage resulting in systemically elevated lipid levels.  Therefore, a lack of 
hyperplasia, coupled with a high prevalence of hypertrophic adipocytes, results in a 
limited capacity of adipose tissue to expand and store fat.  An individual’s capacity 
for adipose expansion is determined by both genetic and environmental factors and 
once the adipose tissue expansion limit is reached, adipose tissue ceases to store 
energy efficiently.12  When the storage capacity of adipose tissue is exceeded, lipids 
can no longer be safely cleared from the systemic circulation and the excess of 
circulating free fatty acids will be deposited in non-adipose organs including the liver, 
skeletal muscle, heart, and the pancreas.12, 13  This is known as lipotoxicity and 
accounts for many of the adverse effects of obesity, particularly changes in 
adipokine release and a low-grade inflammatory response that ultimately lead to 
metabolic dysfunction including reduced insulin sensitivity and glucose intolerance 
(Figure 2).12   
 Healthy adipose tissue is highly vascularized, and each adipocyte is 
nourished by an extensive capillary network.  However, the hypertrophic expansion 
of adipose tissue in obesity is often accompanied by inadequate angiogenesis 
leading to reduced capillary density and local hypoxia.14  Hypoxia is one of the first 
pathological changes to occur in adipose tissue during obesity and is thought to be a 
main driver of fibrosis via the activation of hypoxia-inducible factor 1 (HIF1α) and 
contributes to local inflammation and dyslipidemia (Figure 2).15 12 16   
Adipose tissue dysfunction in obesity results in a shift from an anti-
inflammatory towards a pro-inflammatory profile.  Obesity-associated inflammation 
starts in adipose tissue and liver with elevated macrophage infiltration and 
expression of pro-inflammatory cytokines. The inflammatory response triggered by 
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obesity also results in an increase in the circulating levels of inflammatory cytokines 
such as IL-6 and TNFα, as well as increased acute phase proteins; CRP and serum 
amyloid A (SAA) and causes systemic inflammation.13  Thus, overloaded, 
dysfunctional adipose tissue is associated with the activation of immune cells and 
inflammatory mediators both locally in adipose tissue and systemically resulting in a 
chronic, low-grade, inflammatory state (Figure 2).   
In addition to chronic inflammation, adipocyte overloading and lipotoxicity in 
obesity has a major impact on adipose tissue function resulting an adverse adipokine 
profile (Figure 2).  In particular a reduction in adiponectin production is thought to be 
a major pathogenic factor in metabolic disease.17, 18  Conversely, levels of the pro-
inflammatory adipokine leptin are increased in obesity.19, 20 
The excess supply of energy substrates in obesity is also believed to lead to 
increased mitochondrial dysfunction and reactive oxygen species (ROS) signaling, 
resulting in cellular oxidative stress and impact the endocrine and metabolic function 
of fat cells .21  Obese individuals exhibit higher levels of oxidative stress in white 
adipose tissue, including elevated ROS levels and decreased antioxidant activity 
coupled with alterations in adipokines required for insulin sensitivity.22  Thus, the 
oxidizing environment in adipose tissue of obese individuals impacts fat cell function 
and energy balance. 
Therefore, the excess adiposity that occurs in obesity, is associated with 
adipose dysfunction which in turn contributes directly or indirectly to the development 
of obesity-related diseases.  The accumulation of excessive visceral fat is 
accompanied by alterations at hormonal, inflammatory and endothelial level and as 
such can result in development of a variety of diseases including diabetes, liver 
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disease and cancers. Obesity is also associated with the prevalence of most 
cardiovascular diseases, including systemic hypertension, coronary heart disease 
and PAH. 
 
PAH AND OBESITY 
Epidemiological evidence supports a link between obesity and PAH. Findings 
from the Registry to Evaluate Early and Long-Term PAH Disease Management 
(REVEAL), the largest PH database in the United States indicate that 32% of PAH 
patients are obese.  Furthermore, a higher prevalence of overweight and obese 
individuals among those with idiopathic forms of PAH were observed.2  This 
association appears independent of conditions associated with the development of 
PAH (e.g., diastolic dysfunction, obstructive sleep apnea), suggesting that obesity 
globally disrupts vascular homeostasis and predisposes individuals to the 
development of systemic and pulmonary vascular diseases.  Similarly, in the Scottish 
Pulmonary Vascular Unit incident PAH population and a French multicentre 
population 35.7% and 30% of patients were recorded as being obese respectively.1, 3  
A greater portion of the obese PAH patients recorded were female. 
Obesity has been associated with a significantly worse 6-minute walk time, 
functional class and haemodynamic parameters in PAH patients.1-3  Indeed, a link 
between body weight and the pulmonary vascular function appears to exist.  A 
correlation between BMI and pulmonary artery systolic pressure has been identified 
in otherwise echocardiographically healthy individuals.23, 24  In other studies, BMI 
significantly correlates with right atrial pressure and pulmonary artery pressure in 
incident, treatment naive PAH patients.1  However, some limitations of these studies 
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must be acknowledged as only BMI was assessed and they do not allow for 
differences in adipose tissue distribution or oedema.   
The benefits of weight loss have also been demonstrated in obese PAH 
patients.  Weight loss following bariatric surgery can result in an improvement in 
functional class and tolerance to exercise despite no changes to the PAH therapy 
administered.  This weight loss also contributed to the inhibition of mechanisms 
underlying obese pathology resulting in reduction of insulin resistance, HDL, LDL, 
and free fatty acids that correlate with haemodynamic improvements.25  
PAH and the Obesity Paradox 
Obesity is a well-established independent risk factor for the development of 
cardiovascular disease and mortality.  Nevertheless, substantial data have 
demonstrated an “obesity paradox,” where obese patients generally have a better 
short- and long-term prognosis than their leaner counterparts with the same 
cardiovascular diseases.26  In keeping with this observation, obesity has been 
associated with subclinical right ventricular dysfunction, but paradoxically it may 
confer a protective effect on right ventricular function once the patient develops PH.27  
Analysis of the REVEAL registry found obese PAH patients had a reduced risk of 
death and other studies of a number of PH populations have shown obesity confers 
a survival benefit.2, 28, 29  However, in contrast to this, analysis of PAH patients in 
Scotland over a 20-year period support a French study suggesting there is no 
protective effect from obesity in this disease.1, 3  Furthermore, analysis of PAH 
patient data from the National Institute of Health-PH registry observed that the best 
survival was in the overweight patients rather than obese.29  These studies challenge 
whether an obesity paradox exists in PAH.   
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Animal models of obesity  
A variety of animal models are available to study the effects of obesity on the 
development and progression on PH.  For instance, leptin deficient ob/ob mice lack 
functional leptin, are grossly overweight and hyperphagic, particularly at young ages, 
and develop severe insulin resistance.30  The ob/ob genotype has been shown to 
result in the spontaneous development of PH in both male and female mice, 
independent of left-side heart dysfunction and to recapitulate many of the histological 
features of PH.7, 31  This is consistent with the observation that in humans, increased 
BMI is associated with an increase in pulmonary arterial systolic pressure in both 
males and females.24  However, others have observed that ob/ob mice are protected 
against hypoxia-induced PH due to a decrease in proliferation of their pulmonary 
artery smooth muscle cells (PASMCs).32   
Similar to ob/ob mice, Zucker fatty (ZF)  rats have a mutated leptin receptor 
leading to hyperphagia with obesity apparent from around 3 weeks of age.  ZF rats 
do not become hyperglycemic, but are hyperlipemic, hypercholesterolemic, 
hyperinsulinemic, and develop adipocyte hypertrophy and hyperplasia.33  The ZF rat 
model of obesity also demonstrates hallmarks of PH when aged to 5 months, with 
increases in mean pulmonary artery pressure, right ventricular hypertrophy and 
pulmonary vascular remodelling observed.34 The Zucker diabetic fatty (ZDF) rat is a 
sub-strain of the ZF rat, which was derived from hyperglycemic ZF rats to gain a 
model with diabetic features.35   ZDF rats also develop a PH phenotype at 5 months 
of age.36 
In addition to genetic models of obesity, HFD can also be used to induce 
obesity in animals.  Kelly et al., demonstrated that 20 weeks of HFD feeding in mice 
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results in the development of a pulmonary hypertensive phenotype with elevated 
right ventricular pressure, pulmonary vascular resistance, pulmonary vascular 
resistance and inflammation.37  Similarly, others have shown the development of 
obesity-related PH following HFD feeding in mice with a range of severity in PH 
phenotype depending on the fat content of the diet and the length of the feeding 
regime.38, 39  Pulmonary hypertensive phenotypes can also be observed in certain 
strains of HFD fed rats.34  
It has also been reported that HFD alone does not induce PH per se but can 
be a modifying factor resulting in an increase in the severity of hypoxia-induced PH 
and the penetrance of PH in BMPR2 mutant mice.7, 40  This gives some support to 
the hypothesis that obesity may act as a “second hit” in some individuals and lead to 
the development of PAH.  
Many researchers use a diet containing 60% fat by calories to create obesity 
in mice as they become more obese in a shorter period, thus reducing caging costs.  
In humans, a typical American or European diet will contain ~36–40% fat by energy.  
Therefore, a tolerable high-fat human diet might contain 50–60% of energy as fat.41 
However, a 60% fat rodent diet presents a much greater distortion of the fat content 
of a normal rodent chow which normally contains 10% fat. Thus, the use of the use 
of diets which contain 40-45% fat in rodent studies may be more relevant to human 
physiology. 
A metabolomics study to measure changes in metabolism in mice fed different 
HFDs found a range of significantly altered metabolites including free fatty acids, 
energy metabolites, amino acids, and nicotinamide adenine dinucleotide pathway 
members.  A comparison of these effects between liver, kidney and lung found that 
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few changes were shared across organs, suggesting the lung is an independent 
metabolic organ and that obesity may have direct  mechanistic effects on the lung 
metabolome that can contribute to disease pathogenesis.42  
It should also be noted that adipose depots in rodents do not perfectly 
correlate with those in humans. For instance, the omentum contains a large 
percentage of visceral fat in humans, a depot which is scarcely present in rodents. 
Conversely, the large epididymal fat pads of male mice are frequently sampled as 
representative of visceral fat but do not exist in men.43 
 
MECHANISMS UNDERLYING OBESITY-ASSOCIATED PAH 
   Obesity and PAH share several common pathophysiological mechanisms.  
The initiation of these pathways in obesity may contribute to an environment that 
predisposes obese individuals to the development of PAH.  
PAH, inflammation and obesity 
  Inflammation contributes to both an individual’s susceptibility to PAH and to 
the progression of vascular remodelling in established PAH.44  Autoimmune 
conditions such as systemic lupus erythematosus, systemic sclerosis, and other 
connective tissue diseases are associated with an increased incidence of PAH and a 
wide array of inflammatory markers such as IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, 
IL-18, and TNFα are increased in the serum of PAH patients.45  The levels of these 
inflammatory markers correlate with disease severity or patient survival.46  Various 
studies have also demonstrated perivascular inflammation in PAH lung tissue 
characterised by the presence of numerous immune cells including macrophages 
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and monocytes, lymphocytes, cytotoxic and helper T cells, dendritic cells, and mast 
cells.47 These cells are also present in the occlusive plexiform lesions in the 
pulmonary vasculature of PAH patients. A direct role for perivascular inflammation in 
the pathogenesis of PAH has been suggested as pulmonary perivascular 
inflammation has been shown to correlate with intima and media remodelling.47, 48   
As obesity results in both an enhanced local and systemic inflammatory state 
this may provide a link between the conditions and therefore contribute to the 
development and progression of PAH in obese individuals.  
PAH, oxidative stress and obesity 
 The pulmonary vasculature undergoes morphological changes in PH that can 
be mediated by oxidative stress.  We and others found the expression of various 
oxidative stress markers to change in the lungs and pulmonary vasculature in both 
pre-clinical models7, 49 and clinical PAH.50  In the lungs, endothelial cells, neutrophils, 
eosinophils, alveolar macrophages, and alveolar epithelial cells are all sites of ROS 
production facilitating the pulmonary vasculature to generate ROS by complexes in 
the cell membrane, the cytoplasm, peroxisomes and mitochondria. Enzymes such as 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, uncoupled nitric 
oxide synthase, dysfunctional mitochondria, and xanthine oxidase have all been 
implicated in generating the increased ROS associated with PAH.51  
ROS influence the production of a variety of factors implicated in the 
pathogenesis of PAH and contribute to vasoconstriction and remodelling of the 
pulmonary circulation.  ROS decrease the expression and/or function of redox 
sensitive voltage gated K+ channels (Kv1.5, Kv2.1), ultimately leading to Ca2+ influx 
and smooth muscle cell contraction through the activation of myosin light chain 
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kinase and the subsequent phosphorylation of the myosin light chain.52  ROS can 
also mediate vasoconstriction via the activation of the small GTPase, RhoA, and its 
downstream effector, Rho kinase.53  Furthermore, ROS upregulate potent pulmonary 
vasoconstrictors such as endothelin-1 (ET-1) and thromboxane A2, while attenuating 
the levels of vasodilators, such as prostacyclin and peroxisome proliferator-activated 
receptor gamma (PPAR-γ).51  We have demonstrated that ROS can also contribute 
to estrogen- and serotonin-induced PASMC proliferation and vascular remodelling.  
These mechanisms involve NADPH oxidase 1-mediated ROS production and 
nuclear factor [erythroid-derived 2]-like 2 (Nrf-2) dysregulation that contributing to 
increased post-translational oxidative modification of proteins and activation of 
redox-sensitive signaling pathways.49, 54   
As mentioned previously increased evidence of ROS production is often 
observed in obesity and increased oxidative stress has also been demonstrated in 
the lungs of mice with obesity-induced PAH.7  Thus, oxidative stress and ROS 
production in obesity, particularly in fat depots in close proximity to the pulmonary 
circulation may influence vasoconstriction and the proliferative phenotype of cells of 
the pulmonary vasculature, initiating or contributing to pulmonary vascular 
remodelling in PAH.   
PAH, adipokines and obesity 
 Originally thought to be inert, adipose tissue is now recognized as an 
important endocrine organ releasing an abundance of bioactive mediators called 
adipokines. Adipokine production allows communication between adipocytes and 
other tissues.  The plethora of adipokines identified have the capacity to influence 
every organ system in the body and mediate a diverse array of physiological 
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functions including metabolism, immunity, behaviour, reproduction and 
cardiovascular function.19  
Similar to obesity, serum leptin levels have been shown to be elevated in patients 
with idiopathic PAH (IPAH) and scleroderma-associated PAH independently of pro-
inflammatory cytokines.  Leptin may play a role in the immunopathogenesis of IPAH 
by inhibiting the function of regulatory T cells.  Furthermore, leptin is present in lung 
tissue and a more intense immunoreactivity for leptin in the endothelium of distal 
pulmonary arteries has been observed in IPAH patients versus controls.  Indeed, 
pulmonary artery endothelial cells contribute to the increased secretion of leptin in 
IPAH patients.55  Increased leptin receptor expression has also been shown in 
PASMCs from IPAH patients and that these cells are more proliferative to leptin.56  In 
PAH, plasma leptin levels are directly associated with BMI and lower leptin levels, 
when adjusted by BMI, are associated with an increased overall mortality. The 
leptin/BMI ratio also acts as a high negative predictive value for mortality at 2 years. 
Therefore, leptin levels can predict survival in PAH.57  
The adipokine, adiponectin may provide a link between obesity and PAH due 
to its protective role in the pulmonary circulation.  Animal models demonstrate the 
ability of adiponectin to modulate pulmonary vascular tone, inflammation, and 
remodelling.  For instance, adiponectin-deficient mice have reduced levels of 
endothelial cell nitric oxide in their vascular wall and develop an age-dependent 
increase in pulmonary artery pressure when compared with wild-type mice.58  
Another important function of adiponectin is to tonically suppress vascular 
inflammation. This is exemplified in adiponectin-deficient mice, which develop a 
spontaneous phenotype characterized by activated lung endothelium, age-
dependent increases in perivascular inflammatory cell infiltration and elevated 
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pulmonary artery pressures.58  Furthermore, adiponectin can also inhibit vascular 
smooth muscle cell proliferation by inhibiting growth factor-mediated activation of 
mTOR via AMPK activation.59  Similarly, adiponectin-deficient animals develop more 
prominent pulmonary vascular remodelling in hypoxia-induced PAH.60  By direct 
inhibition of  AMPK/mTOR and NFκB pathways, adiponectin also has anti-
inflammatory properties and indirectly increases circulating levels of apolipoprotein E 
(ApoE) and expression of the PPARγ receptor in the lung.58, 61  
Adiponectin is highly abundant in the circulation of lean healthy individuals, 
however, levels of adiponectin decrease with increasing body mass and circulating 
adiponectin levels are decreased in obesity.  The impaired production of adiponectin 
by adipocytes in obesity is the result of oxidative and endoplasmic reticulum stress 
and the activation of inflammatory cytokines that are prevalent in the adipose tissue 
of the obese.62  Therefore, the reduction in adiponectin in obesity may be influential 
in the development of PAH by impeding its ability to modulate vascular tone, regulate 
inflammatory responses and attenuate vascular smooth muscle cell growth  
However, adiponectin levels are elevated, rather than decreased, in several 
chronic inflammatory diseases. The reason for this paradoxical behaviour is unclear.  
Several studies have also reported an increase in adiponectin levels PAH patients 
rather than a reduction confounding its role in PAH.63, 64  Insulin resistance is 
prevalent in PAH patients and elevated levels of insulin have been shown to 
downregulate AdipoR1/R2 expression limiting adiponectin’s physiological effect and 
resulting in adiponectin resistance.65  Therefore, the increased circulating levels of 
adiponectin in PAH may be a result of the adipose tissues efforts to prevent 
adiponectin functional resistance. 
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Although circulating levels of adiponectin are increased in PAH, 
concentrations within the pulmonary circulation are unknown.  Interestingly in 
patients with PH associated with congenital heart disease although serum levels of 
adiponectin are increased, adiponectin levels within endothelial cells are decreased59 
suggesting the concentration of adiponectin in specific microenvironments may be 
important in contributing to PAH pathogenesis. 
Apelin is an endogenous peptide identified as a ligand of the G protein-
coupled receptor APJ and is widely expressed throughout the body but is 
preferentially produced by visceral adipose tissue with insulin-sensitizing effects.66, 67  
The apelin/APJ system is involved in many physiological processes, such as 
regulation of blood pressure, cardiac contractility, angiogenesis, and energy 
metabolism.  Apelin production is also altered in obesity, with changes in serum 
apelin detected in multiple tissues in obese patients compared to non-obese 
controls.66  These results suggest that apelin might play an important role in obesity 
as apelin inhibits lipolysis in adipocytes 68 and is involved in angiogenesis in adipose 
tissue.69  
Apelin is expressed in the lung, localising in the endothelium of pulmonary 
arteries, whilst the APLNR is present in both endothelial and smooth muscle cells in 
the vasculature.70, 71 Apelin is a pro-survival factor for pulmonary artery endothelial 
cells and can suppress proliferation and induce apoptosis of PASMCs.72   Reduced 
apelin expression has been observed in plasma and pulmonary artery endothelial 
cells from patients with IPAH and has been attributed to their reduced BMPR2 
expression, suggesting that apelin could be effective in treating PAH by rescuing 
BMPR2 and PAEC dysfunction.71, 72  A small randomised double-blind placebo-
controlled study of acute apelin administration in PAH patients during right heart 
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catheterisation has also reported an improvement in cardiac output and pulmonary 
vascular resistance.73  Although changes in apelin production occur in both PAH and 
obesity, studies investigating apelin expression in obesity are inconsistent with both 
increases and decreases in plasma apelin reported.66  However, as with other 
mediators, circulating levels are not always indicative of changes in the local 
microenvironment of the pulmonary circulation and the adipose tissue in its close 
proximity and there is still potential for obesity mediated changes in apelin 
expression to play a role in the development of obesity-related PAH. 
Obesity, insulin resistance and PAH 
 Insulin resistance occurs when insulin-sensitive tissues fail to respond to 
insulin, a phenomenon that is often observed in obesity.   Insulin resistance in 
obesity is manifested by decreased insulin-stimulated glucose transport and 
metabolism in adipocytes and skeletal muscle and by impaired suppression of 
hepatic glucose output.  As mentioned previously, several mediators contribute to the 
development of obesity-related insulin resistance including; inflammation, lipotoxicity 
and hypoxia (Figure 2).74   
 Insulin resistance has also emerged as a potential mechanism related 
to the pathogenesis of PAH.  Based on retrospective data from the National Health 
and Nutrition Examination Survey, female participants with a diagnosis of PAH 
(irrespective of cause) were nearly twice as likely to be insulin resistant (defined as a 
triglyceride/ HDL cholesterol ratio >3.0).75  Similarly, an increased incidence of the 
metabolic syndrome (characterised by insulin resistance, abdominal l and 
hypertension) was observed in patients with pulmonary venous hypertension, a well-
defined cause of PH in patients with left heart disease (WHO Class II).76  A 
subsequent study found that 56% PAH patients had insulin resistance, with 15% 
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patients having unrecognized Type 2 diabetes mellitus (defined as hemoglobin A1C 
(HbA1c) > 6.0% and > 6.5% respectively).77  In addition, there was a trend towards 
lower mean 6-minute walk distance in patients with elevated HbA1c but no 
significant difference in six-month event-free survival (defined as death, 
transplantation, hospitalization for right-heart failure or acute exacerbation of PAH, or 
addition of new vasodilator therapy).77  Furthermore, increased glucose metabolism 
has been observed in the lungs of IPAH patients.78  However, it has yet to be 
determined whether the relationship between obesity, insulin resistance and PAH 
simply represents an association or a cause-and-effect relationship.  
Mutations in the BMPR2 gene are a major cause of heritable PAH (present in 
~80% cases) and have also been reported in ~25-30% IPAH patients.79  An 
association between BMPR2 mutations and insulin resistance has been reported in 
PAH.  A high level of insulin resistance has been observed in mice with an inducible 
BMPR2 mutation and was associated with rapid weight gain.80  In this model insulin 
resistance was present prior to the development of PAH.  The link between BMPR2 
dysfunction and insulin resistance is thought to be mediated by PPARγ, a 
downstream target of BMPR2.   
Genes targeted by PPARγ encode many of the proteins implicated in the 
pathogenesis of PAH including ET-1, IL-6 and adiponectin.62, 81   In addition, reduced 
PPARγ expression has been observed in lungs and circulation of PAH patients.82  
Thus there is increasing evidence that gene regulation by PPARγ plays an important 
role in PAH, indeed PPARγ agonists have demonstrated therapeutic potential for 
PAH in pre-clinical studies.81    
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The BMPR2 dysfunction that occurs during PAH leads to decreased PPARγ 
activity, increased mitogen-activated protein kinase (MAPK) activity and subsequent 
stimulation of pulmonary vascular re-modelling via the platelet-derived growth factor-
β (PDGFR-β) pathway.40, 83  Given that BMPR2-mediated PPAR-γ activation occurs 
earlier than Smad1/5/8 phosphorylation, this appears to be independent of the Smad 
signaling pathway.  ApoE and adiponectin are also important downstream effectors 
of PPARγ, both of which inhibit smooth muscle cell proliferation by converging on the 
PDGFR-β pathway.84   Reduced ApoE expression has been observed in the lungs of 
IPAH patients, suggesting that the BMPR2/PPARγ/ApoE axis may be a key mediator 
of the association between insulin resistance and PAH.85   
PPARγ is abundant in adipose tissue that plays a prominent role in 
adipogenesis, fatty acid storage and is an active modulator of insulin resistance.81  
Activation of  PPARγ in white adipose tissue enhances its ability to store fatty acids 
thus preventing their accumulation in ectopic tissues and reducing the potential for 
insulin resistance to develop.86  Obesity has been reported to inhibit the expression 
and activity of PPARγ contributing to the development of insulin resistance in obese 
individuals.87  Furthermore, activation of PPARγ in adipose tissue may impact 
systemic insulin sensitivity is by altering the production of adipokines.  Transcription 
of adiponectin is upregulation by PPARγ activation and studies have shown that 
plasma adiponectin levels directly correlated with insulin sensitivity.59  Activation of 
PPARγ in adipocytes is also associated with decreased production of TNFα and 
resistin 88 which has been shown to improve insulin sensitivity.    Furthermore, 
thiazolidinedione (TZD) antidiabetic drugs act as PPARγ agonists and have been 
shown to increase the expression of adiponectin and decrease levels of resistin and 
TNF-α human subjects.86  TZDs, pioglitazone and rosiglitazone, have already 
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demonstrated therapeutic potential for PAH in both pre-clinical and clinical trials.89-91  
Beyond the TZDs, nitro-oleic acid (NO2-OA) and it’s isomer CXA-10 (10-nitro-9(E)-
octadec-9-enoic acid) have demonstrated therapeutic potential through stimulation of 
PPARγ, upregulation of Nrf-2 and inhibition of NFκβ.  CXA-10 has successfully 
demonstrated safety in pre-clinical toxicology and Phase I studies, and Phase II 
studies in PAH are currently underway (NCT04053543, NCT03449524).92 
Evidence from animal models with BMPR2 mutations suggests insulin 
resistance develops before PAH and that insulin resistance has a causative role in 
the development of pulmonary vascular disease.80  As insulin resistance is common 
in obesity this may provide another mechanism linking obesity to the development of 
PAH.  
As can be seen in Figure 2, recruitment of inflammatory cells, localised 
inflammation, alterations in adipokine secretion and insulin resistance are all 
interlinked in obese individuals and contribute to metabolic syndrome and systemic 
disease.  The activation of these pathways may also contribute to the onset of 
obesity-related PAH as these pathways are also active in many PAH patients.  As 
discussed later in this article, the changes in adipose tissue and increased adipose 
deposition in close proximity to the pulmonary circulation are likely to have a 
profound effect on the local microenvironment in the lung.  In particular the changes 
in inflammatory mediators and adipokines are known to impact on the expression of 
the estrogen synthesising enzyme aromatase that has been implicated in the 
pathogenesis of PAH. 
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ADIPOSE-DERIVED ESTROGENS AND PAH 
 Estrogens are steroid hormones and play key role in the development of 
secondary sex characteristics.  They are also important in regulating memory, bone 
density and have been shown to have cardiovascular effects. The three major 
estrogens are estrone, estradiol and estriol.  Pre-menopause, estrogen synthesis 
occurs mainly in the ovarian follicles and corpus luteum. In postmenopausal women 
and in men, estrogen is instead produced by extragonadal sites including adipose 
tissue where it acts locally in a paracrine fashion or can be released into the 
circulation. After menopause, adipose tissue is the primary source of estrogen 
production in the body.6   
Adipose tissue interconverts stored or circulating sex steroids but does not 
synthesis sex steroids de novo.  Circulating C19 steroid precursors androstenedione, 
dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEA-S) act as a reservoir 
for extragonadal estrogen synthesis.6  In particular aromatase, 17β-Hydroxysteroid 
dehydrogenases (17βHSDs), and CYP1B1 are highly expressed in adipose tissue 
stromal cells and preadipocytes.93   Aromatase (CYP19A1) is a member of the 
cytochrome P450 superfamily and synthesizes estrogens through the aromatization 
of androgens, specifically testosterone and androstenedione resulting in the 
formation of estradiol and estrone, respectively.  17βHSD mediates the conversion of 
weak androgens or estrogens to their more potent counterparts: androstenedione to 
testosterone and estrone to estradiol (Figure 2).6 
Given the mass of adipose tissue, the relative contribution of adipose tissue to 
whole body steroid metabolism is significant.  BMI is positively associated with tissue 
levels of estrogens.6  Thus, as fat mass increases in obesity, aromatase expression 
and consequently estrogen levels, are also elevated, an effect that is more 
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prominent in postmenopausal as after menopause adipose tissue is the primary 
source of estrogen production in the body.94-96  Adipose tissue can contribute up to 
100% of circulating estrogen in postmenopausal women and 50% of circulating 
testosterone in premenopausal women. The ratio of 17βHSD to aromatase is 
positively correlated with central adiposity, implicating increased local androgen 
production in visceral adipose tissue.93, 97  Thus, adipose tissue is an important site 
for both metabolism and secretion of sex steroids.  
 
Obesity and aromatase  
Many obesity-related factors including changes in the profile of inflammatory 
mediators and adipokines can modulate aromatase gene expression resulting in its 
upregulation.  Expression of aromatase in extragonadal tissues such as adipose is 
regulated by tissue-specific promoters so aromatase action can generate high local 
levels of estrogen with significant biological influence, without significantly affecting 
circulating levels.98  The link between obesity and changes in estrogen synthesis and 
metabolism have been extensively studied in the context of breast cancer.   
 A number of studies have investigated the association between obesity 
and local estrogen production, identifying several factors dysregulated in obese 
adipose tissue that induce aromatase expression in adipose stromal cells.   A variety  
of proinflammatory mediators and cytokines (e.g. prostaglandin E2 (PGE2), TNFα, 
IL-1, IL-6 and cyclooxygenase-2) that are elevated in obesity are known to regulate 
estrogen production in adipose tissue by upregulating aromatase expression (Figure 
3).6  For instance elevated PGE2 levels in obesity may inhibit p53 which is a 
negative regulator of aromatase expression resulting in elevation in aromatase.99 
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Furthermore, IL-6 in serum of obese individuals was found to induce PGE2 secretion 
from breast cancer cells, which in turn induced aromatase expression in primary 
adipose stromal cells.100  PGE2 can also increase aromatase expression by inhibiting 
the LKB1/AMPK pathway, removing its inhibitory effects on cAMP-responsive 
element binding protein-regulated transcriptional co-activators (CRTCs) thus 
resulting in the upregulation of aromatase.101  
Adipokines also play a role in regulating aromatase expression.  The 
LKB1/AMPK pathway is normally activated by adiponectin, leading to suppression of 
aromatase transcription.102  However, adiponectin secretion is markedly reduced in 
obesity and may therefore result in an increase in aromatase expression.  
Furthermore, leptin levels are increased in obesity and result in the inhibition of p53 
and the subsequent upregulation of aromatase.103 
Therefore, aromatase and estrogen production are increased in dysfunctional 
obese adipose tissue, at least in the context of breast cancer.   However, BMI does 
not account for volume or type of body fat and may therefore not be the best 
predictor of local estrogen levels in obesity.  This is highlighted by a study showing 
that inflammation and other systemic markers of metabolic syndrome in white 
adipose tissue from the breast of women with a normal BMI, strongly correlate with 
aromatase expression and activity.104  
Obesity, estrogens and PAH 
Female sex is a clear risk factor for PAH and has given rise to the hypothesis 
that female sex hormones, primarily estrogens, may play a causative role in the 
development of the condition.105  Single nucleotide polymorphisms in the genes 
encoding aromatase and ESR1, that result in elevated estrogen production, have 
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been associated with an increased risk of portopulmonary hypertension (PPHTN).106, 
107 Expression of aromatase has also been identified in lung tissue and pulmonary 
arteries of animal models and in patients with PAH, localising mainly to the vascular 
smooth muscle.108  The concentration of estrogen in the pulmonary artery may 
therefore be much greater than circulating concentrations due to local synthesis and 
exert a powerful influence on the pulmonary vasculature. In support of this, levels of 
estrogen in human PASMCs derived from PAH patients are high.109 Interestingly, 
females were found to express significantly higher levels of aromatase in lung tissue 
and in PASMCs than males.  Indeed, the increased capability of female PASMCs to 
produce estrogen locally via aromatase contributes to a reduction in the BMPR2 
signaling axis and may contribute to the pathology and increased incidence of the 
disease in females 108, 110. 
Sexual dimorphism in the role of aromatase and estrogen can also be seen in 
animal models of PH.  Inhibition of endogenous estrogen synthesis with anastrozole 
reduces moderate and severe experimental PH and restores BMPR2 signaling in 
female animals but not male.108  Inhibition of endogenous estrogen with anastrozole 
and fulvestrant also has beneficial effects in female BMPR2 mutant mice 111 and 
metformin can exert therapeutic effects in females SUGEN/hypoxia rats, in part via 
aromatase inhibition 112.  Clinically,  circulating estrogen levels are elevated in men 
and post-menopausal women with IPAH.113, 114   
 The therapeutic potential of aromatase inhibition has also been demonstrated 
in a small-scale clinical trial using anastrozole.  In this study anastrozole was found 
to be safe, well tolerated, and improved 6-minute-walk distance in postmenopausal 
women and men 115. Notably, many of the participants enrolled in this study were 
overweight or obese. 
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Endogenous estrogens can also play a role in experimental PH in obese mice.  
Both male and female leptin-deficient ob/ob mice spontaneous develop PH and we 
have shown this can be attenuated by inhibiting endogenous estrogen production 
using the aromatase inhibitor anastrozole.  In this study, aromatase expression in 
visceral adipose tissue was significantly higher in lean females than males.  
Furthermore, a marked increase in aromatase expression in visceral adipose tissue 
was observed in obese males but not female.7  We have previously demonstrated that 
anastrozole treatment is only therapeutic in female hypoxic rodents and not males, 
suggesting endogenous estrogens play a more prominent role in the development of 
PH in females. However, we showed that anastrozole can have therapeutic effects in 
male hypoxic mice that are obese and this effect that is likely due to increased 
peripheral production of estrogen and its metabolites.7  Therefore, in addition to clinical 
observations, these finding provide further evidence that endogenous estrogens are 
involved in the development of PAH males, especially in the presence of modifying 
factors such as obesity.  
 Obesity may particularly predispose males to the development of PAH due to 
obesity-mediated adipose dysfunction resulting in altered estrogen production and 
metabolism.7  Obstructive sleep apnea (OSA) is common in obese men 116 , in which 
elevated circulating estrogen levels occur because of the high expression and activity 
of aromatase within adipose tissue 117, 118.  OSA is also associated with the 
development of WHO group 3 PH. Thus, changes in aromatase expression and 
estrogen production clinically and experimentally suggest that endogenous estrogen 
may contribute to the pathobiology of PAH in both males and females by sexually 
dimorphic mechanisms. 
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The enhanced production of estrogen in adipose tissue during obesity, and 
the release of endocrine factors from adipocytes and stromal cells within fat depots 
can promote cell growth and have been linked with development of various cancers, 
including breast cancer.6  There is thus a strong link between obesity driven 
adipose inflammation and estrogen biosynthesis in pro-proliferative disease. As 
these signaling pathways converge in obese PAH patients, they may contribute to 
the development of obesity-related PAH.   
Obesity and CYP1B1 
CYP1B1 is a member of the cytochrome P450 enzyme family 1, subfamily B, 
polypeptide 1, and is constitutively expressed in various tissues including fat, heart, 
and lung.  In addition to the oxidation of xenobiotics, CYP1B1 is involved in the 
metabolism of many important physiological compounds, including estrogen.119  
Compounds formed following the metabolism of estrogen by CYP1B1 exert a wide 
array of physiological effects and have been associated with various cancers.  
CYP1B1 also plays an important role in adipogenesis and obesity.   CYP1B1 is 
highly expressed in white adipose tissue in humans and its expression increases 
upon adipogenic stimulation.120  A review of obesity-related genome-wide 
sequencing studies indicated that CYP1B1 was one of three highest scoring genes 
associated with obesity.121  Animal models further indicate a role for CYP1B1 in 
obesity.  A high fat diet (HFD) has been shown to increase CYP1B1 expression in 
adipose tissue in mice, whilst CYP1B1 deficiency attenuates HFD-induced obesity 
and improves insulin sensitivity without changing calorific intake, suggesting 
CYP1B1 may modulate energy metabolism.119   Furthermore, inhibition of the aryl 
hydrocarbon receptor, an upstream activator of CYP1B1 expression, resulted in the 
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downregulation of CYP1B1 and inhibited hypertrophy and hyperplasia in visceral 
adipose tissue, reversing the effects of HFD.122  
Changes in CYP1B1 mediated estrogen metabolism in obesity have not been 
well studied.  However, we have shown that CYP1B1 is upregulated in white adipose 
tissue in obese mice and is involved in mediating the production and release of the 
mitogenic estrogen metabolite 16OHE1.7 
Obesity, estrogen metabolism and PAH 
Estrogen metabolism also plays a key role in PAH.  As described above, there 
is an abundance of CYP1B1 in adipose tissue.  CYP1B1, mediates C-16 
hydroxylation of estrogen resulting in the formation of the metabolites 16OHE1 and 
16α-hydroxyestradiol (16OHE2) (Figure 4).  CYP1B1 over-expression has been 
observed in PASMCs from both idiopathic and hereditary PAH patients, and various 
SNPs in CYP1B1 have been associated with increased disease penetrance.8, 123  
Conversely, EBV-immortalized B-cells cultured from female heritable PAH (HPAH) 
patients have tenfold lower expression of CYP1B1 than control groups.  A reduction 
in CYP1B1 was not observed in these cells when cultured from male HPAH 
patient.124   This may reflect phenotypic difference in cell type compared to primary 
cultures of  human PASMCs. In addition, estrogen influences B cell maturation and 
selection and may account for the differences observed in , EBV-immortalized cells 
and in males and females.125 Furthermore, the BMPR2 ligands, BMP2 and BMP4 
also have roles in the development, growth potential, and apoptosis of B cells.126   As 
the B-cells studied were from HPAH patients with dysfunctional BMPR2 signaling 
they may be phenotypically altered resulting in changes to estrogen metabolism and 
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differential expression of CYP1B1 compared to human PASMCs from HPAH 
patients. 
 We have shown that serum 16OHE1 and 16OHE2 accumulate in IPAH 
patients, with 16OHE1 levels relating to disease severity.127  The levels of 16OHE1 
in PAH patients are sufficient to cause proliferation of human PASMCs.8, 54  16OHE1 
itself can induce PH in mice.8  Pharmacological inhibition of CYP1B1 using 
tetramethoxystilbene (TMS) also demonstrates therapeutic effects in animal models 
of PAH7, 8  and attenuates estrogen-induced proliferation in PASMCs.8  In particular, 
TMS has beneficial effects in a model of obesity-related PAH.7  The CYP1B1 
metabolite, 16OHE1 also has potent mitogenic effects in the pulmonary circulation 
via mechanisms involving ROS production.8, 54  16OHE2 can also cause proliferation 
of human PASMCs and migration of blood outgrowth endothelial cells derived from 
PAH patients at concentrations observed in IPAH patient serum.127 Additionally, 
plasma levels of the estrogen metabolite 16OHE2 have been demonstrated to 
accumulate in patients with PPHTN.107 
As discussed previously elevated CYP1B1 is associated with obesity and 
metabolic syndrome, playing an important role in increasing adiposity and insulin 
resistance.  Furthermore, leptin is known to upregulate CYP1B1 expression and in 
breast cancer cells.128  Therefore, the increase in leptin levels in obesity may 
contribute to the increase in CYP1B1 expression observed.  We have shown that 
CYP1B1 is also highly expressed in adipose tissue and thoracic adipose tissue from 
obese mice produces 16OHE1.7  This may contribute to the pulmonary hypertensive 
phenotype of obese mice as TMS can prevent the development of PH in these 
animals.7  The close proximity of thoracic fat to the right ventricle and pulmonary 
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circulation may facilitate interactions with adipose derived estrogens and create a 
microenvironment that leads to the development of PAH and/or mediates PAH 
disease progression. 
The estrogen metabolite 2-methoxyestradiol (2MeOE2) is synthesised by 
catechol-O-methyltransferase (COMT) (Figure 4).  We demonstrated that 2MeOE2 
can have beneficial anti-proliferative effects in PAH via inhibition of HIF-1α and 
microtubular disruption.129  Furthermore, 2MeOE2 shares a structural similarity with 
PPARγ ligands thus acts as a PPARγ agonist, stimulates AMPK signaling and 
increases insulin sensitivity.130  COMT deficiency was found to exacerbate the 
effects of HFD-induced insulin resistance in mice.131  Reduced COMT activity and 
2MeOE2 levels have been linked to development of obesity and insulin resistance, in 
addition to PAH.131, 132  The adipokine leptin has been shown to decrease COMT 
expression in breast cancer cells.128  Therefore, the increased leptin levels observed 
in obesity may result in a reduction in COMT and a decrease the levels of the 
2MeOE2 thus attenuating its protective effects on the pulmonary circulation and 
resulting in a more pro-proliferative environment that contributes to the development 
of PAH. 
On the other hand, the pro-proliferative estrogen metabolite 16OHE1 induces 
pulmonary vascular re-modelling and may promote insulin resistance in PAH.7, 9  For 
example, Fessel et al. found that treating BMPR2-mutant vascular smooth muscle 
cells with 16OHE1 significantly decreased mobilisation of the glucose transporter 
Glut4 in response to insulin, and expression of PPAR-γ and lipid transporter CD36.9  
Based on a proof-of-concept study, 16OHE2 has recently been hypothesized to be a 
mediator of PAH.127  However, much research is required to test this hypothesis in 
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vitro and in vivo, and whether this has a similar effect to 16OHE1 in promoting insulin 
resistance is yet to be investigated. 
 Evidence is growing for the role of estrogen and its metabolites in the 
pathogenesis of PAH.  Adipose derived estrogens play a major role in the 
development of breast cancer and it is therefore plausible that they also contribute to 
the pro-proliferative changes that occur in the pulmonary circulation in PAH.  In 
obesity, the increased production of estrogen by adipose tissue influences circulating 
estrogen levels that in turn may have direct effects on the lung.  Furthermore, 
changes in adipokines and inflammatory cytokines may also affect the expression of 
aromatase within lung tissue resulting in changes in the estrogenic profile of the lung 
and contributing to a pro-proliferative environment.  The upregulation of CYP1B1 in 
obesity is likely to contribute to an increase in the presence of 16α-hydroxyestrogens 
that have also been associated with PAH.  Elevated CYP1B in obesity contributes to 
insulin resistance which has also been linked to the development of PAH.  Thus 
obesity-related changes in estrogen metabolism may contribute directly and 
indirectly to the pathogenesis of PAH (Figure 5).    
  
CONTRIBUTION OF SPECIFIC FAT DEPOTS TO PAH 
The distribution of adipose tissue is of great importance with regards to obesity 
related co-morbidities.  Adipose tissue develops in multiple discrete locations and the 
most common classification groups white adipose tissue into subcutaneous and 
visceral categories. Subcutaneous fat is located in upper and lower body regions and 
is the most prominent white adipose tissue depot in lean healthy individuals 
comprising ~80% of all adipose tissue.133  Localised within the visceral compartment, 
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visceral adipose tissue is highly metabolically active and continually releases free 
fatty acids into the portal circulation.134  Many obese individuals accumulate fat intra-
abdominally in visceral deposits.  This is known as central obesity and the excess 
visceral adiposity leads to an array of cardiovascular disease risk factors known as 
metabolic syndrome.135   
Evidence from animal models and cultured adipocytes suggests that the 
preserved expansion capability of subcutaneous white adipose tissue mitigates 
extensive visceral and hepatic fat accumulation and gives some protection against 
metabolic disease.136  Indeed, lower body subcutaneous white adipose tissue does 
not correlate with risk factors for metabolic syndrome, potentially due to slower free 
fatty acid turnover, higher levels of adipocyte hyperplasia and lower levels of 
inflammation.137   
   In addition to major white adipose tissue depots, distinct tissue-associated 
depots are distributed throughout the body, including adipocytes within the dermis, 
skeletal muscle and the epicardial fat pad. These depots are often small, intricate, 
and closely associated with anatomical structures.  They perform novel tissue- and 
organ-specific functions and allow adipocytes to exert profound influence on the 
neighbouring tissue.138, 139  Significant regional differences in adipocyte behaviour 
have been characterised and recognition of their importance is rapidly growing.140  
However, how the local microenvironment influences the function of adipose tissue 
and its impact on systemic metabolism remains largely unexplored.  
Growing evidence implicates aberrant inflammation, ROS and estrogen 
metabolism in PAH pathogenesis, playing an active role in PAH pulmonary vascular 
remodelling. However, mechanisms that trigger crosstalk between these pathways 
and components of the pulmonary circulation are still unclear.  Could tissue specific 
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fat depots in close association with pulmonary and cardiac tissue be the link and 
contribute to the development of obesity-related PAH?  
Perivascular adipose tissue (PVAT) and PAH 
PVAT plays an important role in modulation of vascular physiology.  The 
phenotype of PVAT is distinct from other fat deposits and varies depending on 
location.  Around small vessels PVAT is comprised of adipocytes that are less 
differentiated and vascularized than typical white adipose tissue.  Perivascular 
adipocytes also express higher levels of angiogenic factors such as vascular 
endothelial growth factor, hepatocyte growth factor and thrombospondin.  In healthy 
individuals PVAT normally has protective anti-proliferative, anti-inflammatory and 
anti-contractile effects on the vasculature.141 
The adipocyte dysfunction that occurs in obesity causes inflammation, 
oxidative stress and hypoxia resulting in a loss of the protective effects of PVAT.  For 
instance, increases in TNFα and ET-1 have been observed in the PVAT of small 
arteries isolated from biopsies of visceral fat in obese individuals resulting in 
impaired nitric oxide release.142  Dysfunctional PVAT in obese individuals may also 
result in oxidative stress and the recruitment of immune and inflammatory cells to the 
perivascular layer of pulmonary arteries contributing to vascular remodelling and 
endothelial dysfunction in PAH.143  Additionally, perivascular adipocyte expansion 
has also been linked to the development of vascular insulin resistance as it releases 
a variety of factors including IL-6, IL-8 and MCP-1 that have been shown to affect 
insulin sensitivity locally in a variety of vascular beds.144  Given the important 
contribution of insulin resistance to the pathogenesis of PAH, the potential for PVAT 
expansion in obesity to influence insulin sensitivity may contribute to the 
development of PAH in some obese individuals.  PVAT expansion in obesity within 
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the human lung has not been characterised.  However, in the SUGEN/hypoxia rat 
model of PAH, intense lipid staining in close proximity to the lung vasculature was 
observed in lung sections of both control and PAH animals. The pattern of staining 
was localized around the lung vasculature and asymmetric, which suggests the 
existence of lipid-laden cells within the lung and shows their irregular accumulation in 
proximity to the lung vasculature.145  Further studies in this area are required to 
elucidate the potential role of PVAT in the pathobiology of PAH. 
Cardiac fat and PAH 
Cardiovascular adipose tissue may be of particular importance in the context 
of PAH.   In the thorax, two main adipose depots surround the heart: epicardial and 
pericardial adipose tissue.  Epicardial adipose is particularly important in normal 
heart function and can contribute to the pathogenesis of cardiovascular diseases.  
Epicardial fat represents a small fraction of overall visceral fat but can exerts a 
profound effect on cardiac function.146 
Located between the myocardium and the visceral layer of the pericardium, 
epicardial fat covers approximately 80% of heart's surface area.  Epicardial 
adipocytes are similar to white adipocytes in other white adipose tissue depots but 
express high levels of the UCP-1 and as a result can actively generate heat.  This 
may provide the heart with thermal protection, in addition to mechanical 
cushioning.147  Furthermore, high levels of free fatty acids are produced by epicardial 
fat that can directly diffuse to the adjacent myocardium, acting as an additional local 
energy source.148  Epicardial adipose tissue also secretes a plethora of adipokines 
that have a major effect on the function of the heart and coronary arteries.146   
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Obesity-related dysfunction of the epicardial fat pad can have a profound 
effect on cardiovascular function.  The increase in epicardial adipose tissue 
deposition and infiltration into the myocardium in obese individuals has been shown 
to have adverse effects on heart function.  Increased mass due epicardial adipose 
tissue expansion increases the workload on the heart and contributes to cardiac 
hypertrophy.  Additionally, obesity results in an increase in adipose-derived pro-
inflammatory signaling that can have further detrimental effects on heart and 
vascular function.148 
Increased lipid deposition has been observed in cardiomyocytes in the right ventricle 
of pulmonary hypertensive BMPR2 mutant mice.  Similarly, lipid deposition has also 
been found in the failing right ventricles of HPAH patients, suggesting a lipotoxic 
cardiomyopathy may occur within the right ventricle in PAH.149  
Therefore, in obese individuals epicardial adipose tissue and ectopic lipid 
disposition in cardiomyocytes may contribute to the development of an inflammatory 
and insulin resistant microenvironment in close proximity to the right ventricle and 
pulmonary circulation that has powerful physiological effects resulting in the 
development and progression of PAH and contributing to a dysfunctional right 
ventricle.     
Thoracic adipose tissue is of particular interest in PAH, as its lymphatics drain 
directly into the pulmonary circulation and it can exert local and systemic effects.43  
Interestingly, a recent study investigating the association of thoracic visceral fat with 
PH in patients with advanced lung disease referred for lung transplantation found 
that lower levels of thoracic fat were associated with a higher risk of PH.150  While 
obesity is associated with PAH, some local fat depots may produce mediators such 
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as vaspin and adiponectin that have a cardioprotective effects and contribute to 
obesity paradox observed in some PAH cohorts.  Estrogen produced by thoracic fat 
may also have protective effects on heart function in the context of PAH as animal 
models of the condition have demonstrated cardioprotective effects of exogenously 
administered estrogen.151, 152  For instance, estrogen via estrogen receptor α, 
increases BMPR2 and apelin in the failing right ventricle experimental PAH.153.  
Human atrial and epicardial adipose tissue express aromatase and in rodents 
aromatase mediated estrogen production is significantly elevated with obesity-
related cardiac adiposity and associated atrial arrhythmogenicity.154  We have 
recently demonstrated that thoracic fat from obese mice releases 16OHE1, which is 
known to play a role in pulmonary vascular remodelling in PAH.7  However further 
studies are needed to determine the exact contribution of estrogens derived from 
thoracic fat to right heart function and how they may be involved in PAH. 
Sexual dimorphism in adipose tissue distribution and function 
 Sexual dimorphism in the distribution of adipose tissue is well 
documented.  On average women have a higher percentage of body fat than men 
and store more fat in subcutaneous areas, especially in the gluteal and femoral 
depots.155  Conversely, men accumulate fat preferentially in upper‐body and visceral 
compartments.156  At comparable levels of total adiposity, women have more 
subcutaneous adipose tissue both in the abdominal and in the gluteofemoral area.5  
Furthermore, functionally active areas of brown adipose tissue are present more 
frequently in women than in men.157  The preferential distribution on fat in 
subcutaneous gluteal and femoral fat depots in women is also associated with lower 
metabolic risk.155   
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Evidence suggests that sex steroids play an essential role in fat distribution as 
sex differences in adiposity emerge during puberty and menarche and tend to 
diminish at menopause, when female sex hormone patterns change and fat 
distribution in women shifts toward that of men, and women develop more central 
obesity that contributes to an increase in their incidence of cardiovascular and 
metabolic disease.158  Evidence suggests that estrogen, acting directly or through its 
receptors can differentially augment sympathetic tone resulting in lipid accumulation 
in the subcutaneous depot in women and the visceral compartment in men.  
Estrogens also influence the expandability of adipocytes enhancing the expandability 
subcutaneous adipose tissue whilst inhibiting the expansion of visceral depots.159  
Therefore the reduction in estrogen levels likely contribute to the changes in adipose 
tissue distribution following menopause.  
An increase in the deposition of fat around the heart and aorta has been 
observed in peri- and postmenopausal women independent of age, obesity, and 
other covariates and is associated significantly with a decline in circulating estrogen 
levels.160  Furthermore, data from the Framingham Heart Study found associations 
between pericardial and periaortic fat and coronary heart disease risk factors are 
significantly stronger in women than men,161, 162  suggesting these fat depots play a 
role in the higher risk of coronary heart disease reported in women after menopause.  
Major PAH registries have recently reported an increased mean age of PAH onset, 
with the US REVEAL and European COMPERA registries reporting the mean age of 
onset as 53 and 59 years respectively, therefore many women will be peri- or 
postmenopausal at time of diagnosis.163, 164  No information on changes in adipose 
tissue distribution during menopause have been documented in PAH cohorts, but 
given that the increase in visceral adipose deposition that occurs in women during 
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this time is associated with the occurrence of other cardiovascular diseases it is 
likely it may also be associated with PAH. 
 Numerous studies have established that there are sex-dependent differences 
in the function of adipose tissue.  For instance, women have higher 
circulating adiponectin levels compared with men.165  Animal models have also 
demonstrated sexual dimorphism in the function of adipose depots and adipokines 
within the cardiovascular system.  Elevated levels of resistin in PVAT from males 
compared to females contributes to the sex-dependent differences in resistance 
vessel function in the Spontaneously Hypertensive Stroke Prone Rat resulting in a 
reduction in the protective effect of PVAT.166  Estrogen has been shown to 
downregulate resistin expression both in vivo and in vitro and may account in part for 
the sex-differences observed in PVAT function.167  Additionally, PVAT surrounding 
porcine coronary arteries from females has an anti‐contractile effect mediated by 
adiponectin that is not observed in males, proving further evidence that PVAT may 
function differently in males and females.168 
Currently few studies have investigated the role of specific fat deposits and 
the mechanisms by which they may contribute to obesity-related PAH.  Adipose 
tissue is a major source of estrogen production and sexual dimorphism has already 
been reported in signalling mediated by estrogens in the PAH pathogenesis.  As 
discussed above estrogen is also thought to mediated many of the sex differences in 
adipose tissue distribution.  Studies phenotyping adipose distribution in male and 
female PAH patients may yield some clues as to the contribution of specific fat 
depots to PAH.  Given the large number of women diagnosed with PAH the 
contribution of changes in adipose tissue distribution and function observed during 
menopause is also highly relevant.  A full understanding of the mechanisms by which 
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adipose tissues accumulate in specific depots and how they differ metabolically 
depending on sex may give important insight into how obesity-related PAH develops 
and yield novel therapeutic strategies.  
 
ADIPOSE-DERIVED ESTROGENS AS A THERAPEUTIC TARGET 
Given the growing levels of obesity and the pivotal role of adipose tissue in 
metabolic health and disease, adipose tissue has potential as a direct or indirect 
therapeutic target in the treatment of obesity-related PAH.  Given the substantial role 
of adipose tissue in estrogen production, modulation of sex steroids may be of 
particular benefit in the treatment of PAH.  In particular, obese PAH patients may 
respond well to any novel therapies that reduce the influence of estrogens. Drugs 
that inhibit estrogen synthesis and attenuate the effects of estrogens are now in 
clinical trials for PAH. 
 Aromatase inhibitors are already widely used in the treatment of estrogen-
sensitive breast cancer.  Genetic variations in estrogen signaling have been 
associated with PAH.106  In addition men and postmenopausal women with PAH 
have higher levels of estrogen compared with controls and  this correlates with 
shorter six-minute walk distance.169, 170  These data have led to clinical trials of 
treatments targeting the sex hormone profile of PAH patients.  A small placebo-
controlled randomized clinical trial of the aromatase inhibitor anastrozole showed a 
reduction in circulating estrogen levels and a significant increase in 6MWD over a 12 
week period.115  A larger phase II randomised clinical trial of anastrozole in PAH is 
currently enrolling (NCT03229499). 171  
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Increased expression of estrogen receptors have been observed in PASMCs 
from PAH patients, with estrogen receptor alpha (ERα) increased in females, whilst 
estrogen receptor beta (ERβ) is increased in males.172 This makes blocking estrogen 
receptors an attractive target to mitigate the effects of estrogen in the pathogenesis 
of PAH.  Fulvestrant is an estrogen receptor antagonist currently used in the 
treatment of breast cancer that can inhibit the function and decrease the expression 
of estrogen receptors.  In a small proof-of-concept study (NCT02911844), fulvestrant 
administration resulted in a higher 6MWD, increased stroke volume, and a decrease 
in αOHE2 levels in postmenopausal women with PAH.173  The reduction in 16OHE2 
may account for some of the beneficial effects observed as this estrogen metabolite 
has previously been linked to portopulmonary hypertension.107 Combined 
administration of fulvestrant and anastrozole has also been shown to result in a 
marked improvement in hemodynamics and pulmonary vascular remodelling in a 
BMPR2 transgenic mouse model of PAH.111 
Tamoxifen is the most commonly used selective estrogen receptor modulator 
(SERM) and acts as an antagonist at ERα and ERβ although can have a partial 
agonist effect in some tissues.  It has been shown to have therapeutic effects in a 
murine model of PAH.111  A small, double blind, randomised, placebo-controlled, 
proof of concept Phase II trial to determine the safety of tamoxifen in males and pre-
and post-menopausal females is currently underway (NCT03528902).  Due to their 
strong anti-estrogenic nature fulvestrant and anastrozole are regularly used in 
postmenopausal women and not recommended for use in premenopausal women 
due to induction of menopause.  As tamoxifen has some efficacy in preclinical 
studies, and is already widely used in pre-menopausal women, it is important to 
determine whether it can be of therapeutic benefit in younger female PAH patients. 
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CYP1B1 modulators could also be considered as therapeutic agents to 
protect against the metabolic effects of obesity. TMS is a selective, potent CYP1B1 
inhibitor and its beneficial effect on several metabolic diseases, including 
tumorigenesis, hypertension, atherosclerosis, and adipogenesis have been 
determined in animal models.119   As discussed early, TMS has also shown to have 
therapeutic effects in animal model of PH, including obesity-induced PH.7, 8  CYP1B1 
inhibition has also been explored clinically as a therapeutic target.  ZYC300 is a 
CYP1B1-based vaccine which stimulates the immune system to elicit a cytotoxic T 
lymphocyte response against tumour cells expressing CYP1B1.  Phase I trials of 
ZYC300 conducted in late stage cancer patients have shown some promise.174, 175  
 With growing levels of obesity, adipose derived estrogens and their 
metabolites are likely to become the major source of estrogens contributing to the 
development of PAH.    Third-generation aromatase inhibitors such as anastrozole 
have proven more beneficial in supressing estrogen production in adipose tissue in 
men than other sources,176 suggesting aromatase inhibition may have additional 
benefits when administered to obese PAH patients.  Likewise, given the abundance 
of CYP1B1 in adipose tissue, its inhibition may confer a greater benefit when taken 
by obese individuals with PAH. 
  
 
SUMMARY 
The obesity pandemic has highlighted the importance of adipose tissue and it 
is no longer merely considered as a storage organ but is recognized as an important 
endocrine organ essential in regulating metabolic function.  Obesity causes many 
changes in adipose tissue including adipocyte hypertrophy, infiltration of 
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inflammatory cells, fibrosis and altered adipokine secretion.  The resultant adipose 
tissue dysfunction has a variety of systemic and local effects that are also known to 
play a role in PAH.  Therefore, obesity may create a pathophysiological environment 
that facilitates disease development in susceptible individuals and indeed obesity 
related PAH accounts for between 30-40% of PAH patients. 
Obesity mediated changes in adipokine and inflammatory cytokines can result 
in insulin resistance, which is already common in PAH patients.  These mediators 
also affect aromatase expression and estrogen metabolism through CYP1B1, 
processes that are important in PAH pathophysiology.  Ectopic fat deposition in 
obesity, particularly in peri-vascular and cardiac tissue provides a direct link between 
adipose tissue dysfunction and the pulmonary circulation and more studies 
investigating the role of these fat deposits in the pathology of PAH are warranted.  
Adipose tissue distribution and function shows marked sexual dimorphism and given 
the large number of women diagnosed with PAH, studies investigating the 
phenotype of adipose tissue distribution in both sexes are needed. 
Increased adiposity and obesity are associated with aging and the resultant 
chronic low-level inflammation often causes insulin resistance.177    Major PAH 
registries have recently reported an increased mean age of PAH onset, with the US 
REVEAL and European COMPERA registries reporting the mean age of onset as 53 
and 59 years respectively.163, 164  Thus with a globally expanding older population 
(with higher rates of insulin resistance, obesity and other co-morbidities), the 
underlying chronic inflammation and adipose dysfunction is likely to play an 
increasing role in the pathogenesis of PAH.   
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 Whilst current therapeutic strategies for PAH improve exercise 
capacity, quality of life and long-term outcomes, they are still palliative and PAH 
carries a high risk of mortality due to right heart failure.  The 5-year survival rate for 
patients suffering from PAH is around 60%.163  Thus new treatments are required 
and in the era of personalized and precision medicine, increasing our knowledge of 
adipose tissue biology coupled with improved phenotyping of adipose tissue 
distribution and how this contributes to the development of PAH may yield novel 
therapeutic strategies.  
Higher estrogen levels are observed in both sexes and associated with worse 
functional markers of PAH.  This coupled with altered estrogen metabolite profiles 
where elevated 16α-hydroxyestrogens are likely to contribute to PAH make widely 
used anti-estrogenic drugs with well-established safety profiles an attractive 
therapeutic strategy.   Given the large number of obese PAH patients the 
contribution of adipose tissue to this skewed estrogenic profile requires greater 
investigation and obesity should be a consideration when tailoring treatments to 
patients in order to maximise therapeutic benefit.  
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Figure legends 
 
Figure 1.  Adipose tissue dysfunction in obesity.  Insufficient storage capacity of 
adipocytes in obesity results in systemic inflammation, increased lipolysis, hypoxia 
and altered adipokine secretion.  These factors result in the development of insulin 
resistance and metabolic syndrome which further impairs adipose tissue function 
and contributes to obesity-related diseases.  CRP, C-reactive protein; ECM, 
extracellular matrix; FFAs, free fatty acids; HIF1α, hypoxia inducible factor-1; IL-6, 
interleukin- 6; TNFα, tumour necrosis factor-α. 
Figure 2.  Local production of estrogens in human adipose tissue from circulating 
precursors. DHEA, dehydroepiandrosterone; DHEA-S, DHEA sulfate; 17β-HSD, 
17β-hydroxysteroid dehydrogenase; 3β-HSD, 3β-Hydroxysteroid dehydrogenase. 
Figure 3.  Mechanisms mediating the upregulation of aromatase and estrogen (E2) 
production in adipose tissue.  Increased local inflammation due to macrophage 
infiltration in obese adipose tissue results in the production of inflammatory 
mediators know to induce the transcriptional upregulation of aromatase resulting in 
increased E2 production.  COX2, cyclooxygenase-2; E2, estrogen; IL-6, interleukin- 
6; PGE2, prostaglandin E2; TNFα, tumour necrosis factor-α. 
Figure 4: Estrogen metabolism. Estrone (E1) and estradiol (E2) are synthesised by 
aromatase.  Hydroxylation of E1 and E2 occurs at C2, C4 and C16 positions by 
cytochrome P450 enzymes (the most prominent being CYP1A2 and CYP1B1 
promoting beneficial and detrimental hydroxylation, respectively) resulting in the 
formation of  16α-hydroxyestrogens, 2-hydroxyestogens and 4-hydroxyestrogens by 
cytochrome P450 enzymes. The 2- and 4- hydroxyestrogens are converted to 2- and 
4-methoxyestrogens via catechol-O-methyltransferase (COMT).   All E1 and E2 
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metabolites are maintained in equilibrium by 17β-hydroxysteroid dehydrogenase 1 & 
2 (17β-HSD1 and 17β-HSD2) enzymes.  16OHE1, 16α-hydroxyestrone; 16OHE2, 
16α-hydroxyestradiol; 2OHE1, 2-hydroxyestrone; 2OHE2, 2-hydroxyestradiol; 
4OHE1, 4-hydroxyestrone; 4OHE2, 4-hydroxyestradiol; 2MeOE1, 2-methoxyestrone; 
2MeOE2, 2-methoxyestradiol; 4MeOE1, 4-methoxyestrone; 4MeOE2, 4-
methoxyestradiol. 
Figure 5. Changes in estrogen metabolism in adipose tissue and its contribution to 
the development of obesity-related pulmonary arterial hypertension (PAH). Obesity 
causes an increase in the expression of aromatase and CYP1B1 in adipose tissue 
resulting in the increased production of estrogen (E2) and its metabolite 16α-
hydroxyestrone (16OHE1).  In particular, 16OHE1 induces proliferation of pulmonary 
artery smooth muscle cells (PASMCs) and contributes to pulmonary vascular 
remodelling in PAH.  CYP1B1 is also associated with insulin resistance another 
underlying pathology linked with PAH. 
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